CAS 864070-44-0

General Information

Empagliflozin belongs to a class of substances called hypoglycemic agents, which lower glucose levels in the blood. It is indicated as an adjunct to diet and exercise to improve glycemic (blood sugar) control in adults with type 2 diabetes mellitus.


Type 2 diabetes mellitus is a metabolic disorder characterized by high blood sugar in the context of insulin resistance and relative lack of insulin. Orally administered, Empagliflozin exerts its therapeutic effect by inhibiting sodium-glucose co-transporter 2 (SGLT2).


Developed by Boehringer Ingelheim and Eli Lilly and Company, Empagliflozin was approved in the United States and Europe in 2014. It is prepared through a stepwise organic synthetic procedure.

About the API

Systematic name D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)
Trade name(s) Jardiance
Technology Synthetic Organic Chemistry
Molecular Formula C23H27ClO7
Molecular Weight 450.90928
Physical properties non-hygroscopic powder
Therapeutic category Diabetes
Available formulations Oral Solid
Regulations US DMF Flag US DMF